Skip to main content
. 2023 Mar 2;19(1):2177066. doi: 10.1080/21645515.2023.2177066

Figure 1.

Figure 1.

Participant disposition.

Percentages are calculated based on the number of participants randomized. Participants could have been considered to complete the study without receipt of PPSV23. PCV13: 13-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine; V114: 15-valent pneumococcal conjugate vaccine.